Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/09/009650
CTRI/2017/09/009650
Not yet recruiting
Phase 2

Rituximab with reduced dosage LMB backbone chemotherapy schedule in childhood and adolescent mature B cell lymphoma/leukemia: Evaluation of efficacy & toxicity profile in developing country setting - R LMB childhood lymphoma

Cancer Institute adyar0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- Burkitt lymphoma and diffuse large B cell lymphoma

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- Burkitt lymphoma and diffuse large B cell lymphoma
Sponsor
Cancer Institute adyar
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Cancer Institute adyar

Eligibility Criteria

Inclusion Criteria

  • •1\.CD 20 positive Burkitt lymphoma \& Diffuse large B cell lymphoma stage III \& IV stage
  • •2\.CD 20 positive Burkitt lymphoma \& Diffuse large B cell lymphoma stage I \& II stage non\-resectable

Exclusion Criteria

  • •1\.Active hepatitis B infection or carriers of hepatitis B virus
  • •2\.Active hepatitis C infection or carriers of hepatitis C virus
  • •3\.HIV infected children
  • •4\.Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology
  • •5\.Follicular lymphoma, MALT, nodular marginal zone lymphoma and primary mediastinal B cell lymphoma
  • •6\.Children with cardiac dysfunction\- ejection fraction \< 45%
  • •7\.Pregnancy
  • •8\.Allergic to rituximab
  • •9\.Not consenting for treatment
  • •10\.Children assessed by treating physician as not fit for intensive chemotherapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Very low doses of Rituximab for autoimmune diseases, for which rituximab is not approved for - a Pilot TrialAutoimmune-haemolytic AnemiaAntiphospholipid SyndromeImmune-mediated ThrombocytopeniaMedDRA version: 20.0Level: LLTClassification code 10003825Term: Autoimmune hemolytic anemiaSystem Organ Class: 100000154058MedDRA version: 20.0Level: LLTClassification code 10023095Term: ITPSystem Organ Class: 100000157088MedDRA version: 20.0Level: PTClassification code 10002817Term: Antiphospholipid syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-002478-11-ATMedical University of Vienna, Department of Internal medicine I48
Active, not recruiting
Phase 1
Maintenance treatment With rituximab in ITP
EUCTR2015-005276-14-DKSykehuset Østfold HF130
Not yet recruiting
Not Applicable
Study on the efficacy of rituximab in patients with polymyalgia rheumaticapolymyalgia rheumatica
NL-OMON27507one. This is an investigator initiated trial50
Active, not recruiting
Not Applicable
Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)
EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS
Recruiting
Phase 2
Rituximab combined with gemcitabine, dexamethasone, and cisplatin in elderly patients with relapsed or refractory diffuse large B-cell lymphomaDiffuse large B-cell lymphoma
JPRN-UMIN000015492ational Hospital Organization Kyushu Medical Center42